NKP-1339 (Synonyms: KP1339) |
| Catalog No.GC19263 |
Le NKP-1339 (IT-139; KP-1339) est le premier agent anticancéreux À base de ruthénium en cours de développement contre le cancer solide avec des effets secondaires limités. Le NKP-1339 induit l'arrêt du cycle cellulaire G2/M, le blocage de la synthèse d'ADN et l'induction de l'apoptose via la voie mitochondriale. Le NKP-1339 a un potentiel de ciblage tumoral élevé, se lie fortement aux protéines sériques telles que l'albumine et la transferrine et s'active dans le milieu tumoral réducteur.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 197723-00-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NKP-1339(IT-139) is a ruthenium(iii) coordination anticancer compound based on target to transferrin.
References:
[1]. Kuhn PS, et al. Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential. Dalton Trans. 2014 Nov 11.
[2]. Robert Trondl, et al. ChemInform Abstract: NKP-1339, the First Ruthenium-Based Anticancer Drug on the Edge to Clinical Application.
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *